RFA-CA-21-045: Coordinating Center for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (U24 Clinical Trial Required)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants of up to $750,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on December 28, 2021.
From the official notice on Grants.gov, last changed October 26, 2021. Checked November 7, 2026.
- Award ceiling$750,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU24
- Clinical trialsRequired
- Funded byNCI
- Median yearly award$1.4 million
- Typical project length4.5 years
- U24, Resource-Related Research Project Cooperative Agreement. Shared research resources such as data centers or coordinating centers, with substantial NIH involvement. Other open U24 notices.
Projects funded under RFA-CA-21-045 were run by National Cancer Institute (NCI, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-CA-21-045 in the NIH Guide.
Key dates
| Posted | October 26, 2021 |
|---|---|
| Deadline | December 28, 2021 |
| Archived by Grants.gov | February 2, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $1.4 million; it allows up to $750,000 per award.
- Most of the money in the 3 programs behind this notice (58% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network seeks to evaluate innovative approaches for overcoming barriers and reducing failures in the cervical cancer screening and treatment cascade for women living with HIV. The proposed multicenter network will conduct pragmatic clinical trials to evaluate the effectiveness of clinically proven interventions in intended-use settings with a goal to optimize the cervical cancer screening, management, and precancer treatment cascade for women living with HIV. These trials will focus on the health care continuum for secondary cervical cancer prevention, i.e., increasing screening uptake, improving management of screen positives, facilitating precancer treatment access, and optimizing precancer treatments. Data from these trials will be used to provide the necessary evidence to refine clinical practice guidelines and inform public health policy with a goal to generate crucial actionable evidence for improving cervical cancer prevention implementation programs. The U24 cooperative agreement mechanism-funded Network Coordinating Center will coordinate all network activities, including concept and protocol review processes, provide centralized data management support, conduct independent clinical trials auditing for the network trials, and interface with network grantees for augmenting study training, reporting, and quality assurance activities.
Funded under RFA-CA-21-045 so far
NIH funded 1 project under RFA-CA-21-045 in fiscal 2022 to 2026, at 1 institution. The median yearly award was $1.4 million.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| CASCADE Coordinating Center | Frontier Sci & Technology RSCH FDN, Inc | 2026 | $1.4 million |
Who has won Cancer Treatment Research grants before
From fiscal 2021 to 2025, Cancer Treatment Research (93.395) awarded $5.6 billion across 3,622 grant awards, an average of $1.5 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 144 | $188 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 68 | $185 million |
| Icahn School of Medicine at Mount Sinai | New York | 35 | $179 million |
| Public Health Institute | California | 4 | $168 million |
| Fred Hutchinson Cancer Center | Washington | 57 | $156 million |
Who has won Cancer Cause and Prevention Research grants before
From fiscal 2021 to 2025, Cancer Cause and Prevention Research (93.393) awarded $3.6 billion across 2,517 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 81 | $107 million |
| Sloan-Kettering Institute for Cancer Research | New York | 65 | $99.1 million |
| The Trustees of Columbia University in the City of New York | New York | 48 | $85.3 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 51 | $83.1 million |
| University of North Carolina at Chapel Hill | North Carolina | 49 | $76.1 million |
Who has won Cancer Control grants before
From fiscal 2021 to 2025, Cancer Control (93.399) awarded $814 million across 113 grant awards, an average of $7.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Ecog-Acrin Medical Research Foundation, Inc. | Pennsylvania | 1 | $87.9 million |
| NRG Oncology Foundation Inc | Pennsylvania | 1 | $54.3 million |
| Alliance NCTN Foundation | Illinois | 1 | $50.2 million |
| Oregon Health & Science University | Oregon | 2 | $34.4 million |
| University of Rochester | New York | 1 | $29.8 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-CA-21-045 still open?
No. It closed on December 28, 2021.
Who can apply for Coordinating Center for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (U24 Clinical Trial Required)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Coordinating Center for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (U24 Clinical Trial Required)?
Closed December 28, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $750,000 each.
Who has been funded under RFA-CA-21-045?
NIH RePORTER lists 1 project funded under RFA-CA-21-045 in fiscal 2022 to 2026, at 1 institution.
Who has won Cancer Cause and Prevention Research grants before?
The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York. The program made 2,517 awards worth $3.6 billion in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Microplastics Research and Resource Coordination Center (U24 - Clinical Trial Not Allowed)
- IGVF Data and Coordinating Center (U24 Clinical trials Not Allowed)
- Network of the National Library of Medicine Training Center (U24 Clinical Trial Not Allowed)
- Network of the National Library of Medicine Coordinating Center (U24 Clinical Trial Optional)